Eli Lilly reported second-quarter revenue of $23 billion on Wednesday morning, a 48 percent increase from a year earlier. Adjusted earnings came in at $8.38 per share against a Wall Street consensus of $6.01. The stock rose 6 percent before the open.
Twenty-four hours earlier, Novo Nordisk had reported its own second quarter. Revenue was 78.5 billion Danish kroner, roughly $12 billion, with adjusted sales growth of 7 percent at constant exchange rates. The stock fell 5 percent. Novo's full-year guidance projects adjusted sales and operating profit between flat and negative 6 percent compared with 2025.
Two companies. The same patients. One grew 48 percent. The other grew 7.
## The Molecule
The gap traces to a molecular difference. Lilly's tirzepatide targets both GIP and GLP-1 receptors. Novo's semaglutide targets GLP-1 alone. Both reduce weight. Clinical trials have consistently shown tirzepatide produces greater reductions.
Mounjaro, Lilly's tirzepatide for diabetes, generated $9.9 billion in the quarter, up 91 percent. Zepbound, the same compound sold for weight loss, added $4.9 billion in U.S. revenue alone. Two brand names for one molecule produced $14.8 billion in three months. Lilly holds 60.9 percent of the U.S. injectable obesity and diabetes drug market. The company raised its full-year revenue guidance to between $85 billion and $87 billion.
Novo's answer is a pill. The oral Wegovy formulation has exceeded 5 million prescriptions in the United States since launch. But second-quarter pill revenue of 3.22 billion kroner came in below analyst expectations. The European Medicines Agency approved the pill and a higher-dose pen in July. Novo's CEO spent the earnings call defending the pill's economics.
## The Door
On April 30, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of drugs that outsourcing facilities can compound from bulk substances. The agency cited more than 455 adverse events from compounded semaglutide and more than 320 from compounded tirzepatide, including hospitalizations from dosing errors in multi-dose vials. The comment period closed July 30. A final rule is expected this quarter.
When it arrives, the third competitor in the GLP-1 market disappears. Compounding pharmacies had filled the gap during shortages, often at a fraction of the branded price. A market of three becomes two. One of the two is shrinking.
## The Factory
Lilly has invested more than $18 billion in manufacturing capacity since 2020, including a $9 billion campus in Lebanon, Indiana, with initial output expected late this year. Demand still exceeds supply.
Software companies grow at 48 percent by copying code to another server. Lilly grows at 48 percent by producing injectable peptides in sterile facilities that take years to build and validate. Each additional dollar of revenue requires molecules, vials, delivery devices, cold chains, and regulatory clearance. The company is building physical infrastructure to supply a drug that 12.4 percent of American adults already take, while the international market expands faster: Mounjaro's sales outside the United States jumped 172 percent in the quarter, partly driven by China adding the drug to its state-run health insurance coverage for diabetes.
## The Spread
The GLP-1 market is projected to reach $100 billion annually by the end of the decade. Lilly's run rate on Mounjaro and Zepbound alone approaches $60 billion. The 39 percent earnings beat means even the analysts who follow this company most closely underestimated how fast the addressable population is growing. The total addressable market is not a disease category. It is every person who wants their body to be different than it is. That market has no denominator.
Lilly entered this race second. Novo invented GLP-1 agonists, made semaglutide a household word, built Ozempic into one of the most prescribed drugs in history. It mattered until the competitor arrived with a better molecule. First mover, second mover, the rest is arithmetic.